Cancer Stem Cells in Hepatocellular Carcinoma - from Origin to Clinical Implications

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2021 Sep 10

PMID 34504325

Citations 167

Authors

Terence Kin-Wah Lee

Xin-Yuan Guan

Stephanie Ma

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is an aggressive disease with a poor clinical outcome. The cancer stem cell (CSC) model states that tumour growth is powered by a subset of tumour stem cells within cancers. This model explains several clinical observations in HCC (as well as in other cancers), including the almost inevitable recurrence of tumours after initial successful chemotherapy and/or radiotherapy, as well as the phenomena of tumour dormancy and treatment resistance. The past two decades have seen a marked increase in research on the identification and characterization of liver CSCs, which has encouraged the design of novel diagnostic and treatment strategies for HCC. These studies revealed novel aspects of liver CSCs, including their heterogeneity and unique immunobiology, which are suggestive of opportunities for new research directions and potential therapies. In this Review, we summarize the present knowledge of liver CSC markers and the regulators of stemness in HCC. We also comprehensively describe developments in the liver CSC field with emphasis on experiments utilizing single-cell transcriptomics to understand liver CSC heterogeneity, lineage-tracing and cell-ablation studies of liver CSCs, and the influence of the CSC niche and tumour microenvironment on liver cancer stemness, including interactions between CSCs and the immune system. We also discuss the potential application of liver CSC-based therapies for treatment of HCC.

Citing Articles

Radioresistance in Hepatocellular Carcinoma: Biological Bases and Therapeutic Implications.

Wu J, Zhao X, Ren B, Duan X, Sun J Int J Mol Sci. 2025; 26(5).

PMID: 40076465 PMC: 11899467. DOI: 10.3390/ijms26051839.

SLC7A11, a disulfidptosis-related gene, correlates with multi-omics prognostic analysis in hepatocellular carcinoma.

Li S, Wang X, Xiao J, Yi J Eur J Med Res. 2025; 30(1):161.

PMID: 40069889 PMC: 11900568. DOI: 10.1186/s40001-025-02411-y.

FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling.

Wang S, Peng R, Chen C, Tu D, Cao J, Su B Med Oncol. 2025; 42(4):98.

PMID: 40067532 DOI: 10.1007/s12032-025-02644-1.

Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies.

Lv M, Huang Y, Chen Y, Ding K Exp Hematol Oncol. 2025; 14(1):32.

PMID: 40057816 PMC: 11889934. DOI: 10.1186/s40164-025-00622-x.

A high-throughput screening platform to identify expression inhibitors for liver cancer therapy.

Xu Y, Mishra H, Furutani Y, Yanaka K, Nishimura H, Furuhata E Front Oncol. 2025; 15:1486671.

PMID: 40027135 PMC: 11868045. DOI: 10.3389/fonc.2025.1486671.

References

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

Craig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A . Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019; 17(3):139-152. DOI: 10.1038/s41575-019-0229-4. View

Yamashita T, Wang X . Cancer stem cells in the development of liver cancer. J Clin Invest. 2013; 123(5):1911-8. PMC: 3635728. DOI: 10.1172/JCI66024. View

Tsui Y, Chan L, Ng I . Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. Br J Cancer. 2020; 122(10):1428-1440. PMC: 7217836. DOI: 10.1038/s41416-020-0823-9. View

Yang X, Xu Y, Yu B, Zhou J, Qiu S, Shi G . High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010; 59(7):953-62. DOI: 10.1136/gut.2008.176271. View

Miltiadous O, Sia D, Hoshida Y, Fiel M, Harrington A, Thung S . Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. J Hepatol. 2015; 63(6):1368-77. DOI: 10.1016/j.jhep.2015.07.025. View

Yamashita T, Forgues M, Wang W, Kim J, Ye Q, Jia H . EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68(5):1451-61. DOI: 10.1158/0008-5472.CAN-07-6013. View

Zheng H, Pomyen Y, Hernandez M, Li C, Livak F, Tang W . Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018; 68(1):127-140. PMC: 6033650. DOI: 10.1002/hep.29778. View

Ho D, Tsui Y, Sze K, Chan L, Cheung T, Lee E . Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett. 2019; 459:176-185. DOI: 10.1016/j.canlet.2019.06.002. View

10.

Malato Y, Naqvi S, Schurmann N, Ng R, Wang B, Zape J . Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest. 2011; 121(12):4850-60. PMC: 3226005. DOI: 10.1172/JCI59261. View

11.

Tummala K, Brandt M, Teijeiro A, Grana O, Schwabe R, Perna C . Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells. Cell Rep. 2017; 19(3):584-600. PMC: 5409928. DOI: 10.1016/j.celrep.2017.03.059. View

12.

Mu X, Espanol-Suner R, Mederacke I, Affo S, Manco R, Sempoux C . Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J Clin Invest. 2015; 125(10):3891-903. PMC: 4607132. DOI: 10.1172/JCI77995. View

13.

Jors S, Jeliazkova P, Ringelhan M, Thalhammer J, Durl S, Ferrer J . Lineage fate of ductular reactions in liver injury and carcinogenesis. J Clin Invest. 2015; 125(6):2445-57. PMC: 4497753. DOI: 10.1172/JCI78585. View

14.

Shin S, Wangensteen K, Teta-Bissett M, Wang Y, Mosleh-Shirazi E, Buza E . Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice. Hepatology. 2016; 64(4):1163-1177. PMC: 5033674. DOI: 10.1002/hep.28602. View

15.

He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y . Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013; 155(2):384-96. PMC: 4015514. DOI: 10.1016/j.cell.2013.09.031. View

16.

Matsumoto T, Takai A, Eso Y, Kinoshita K, Manabe T, Seno H . Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma. Cancer Res. 2017; 77(22):6131-6143. DOI: 10.1158/0008-5472.CAN-17-1800. View

17.

Ang C, Hsu S, Guo F, Tan C, Yu V, Visvader J . Lgr5 pericentral hepatocytes are self-maintained in normal liver regeneration and susceptible to hepatocarcinogenesis. Proc Natl Acad Sci U S A. 2019; 116(39):19530-19540. PMC: 6765306. DOI: 10.1073/pnas.1908099116. View

18.

Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen M . LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nat Commun. 2020; 11(1):1961. PMC: 7181628. DOI: 10.1038/s41467-020-15846-0. View

19.

Zhou J, Zeng Q, Wang H, Zhang B, Li S, Nan X . MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology. 2015; 62(3):801-15. DOI: 10.1002/hep.27887. View

20.

Ma S, Tang K, Chan Y, Lee T, Kwan P, Castilho A . miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010; 7(6):694-707. DOI: 10.1016/j.stem.2010.11.010. View